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Introduction 
 
 Having active cancer pain has the potential to take a toll on a person’s life in the worst 
ways. Sometimes their whole way of living must change while they try to adapt to the pain. It is 
projected that there will be 1,806,590 new cancer cases in 2020 with a death rate of 606,520 
(Jemal, 2020). The cost for treatments for these types of patients can go up to as much as 
$400,000 per year with one drug costing almost $12,000 per year (Rimer, 2018). Statistics show 
that 33-59% of cancer patients experience pain (Dhingra, 2019). There is a cancer pain 
assessment that will be routinely performed for these types of patients in order to give them a 
therapeutic treatment plan. A pain scale that is currently used in combination with objective data 
often refers to a numerical scale from 0-10, 10 indicating the worst pain and 0 indicating no pain 
(Aono, 2020). Opioids are the first-line treatment for patients with cancer pain for their safety, 
flexibility, through dose titration, opioid rotation, by having multiple routes of administration, 
and effectiveness. Even so, there are many adverse effects, such as constipation, somnolence, 
and mental clouding resulting from the use of opioids, which may end up in a change of therapy 
for many patients (Ahmed, 2020). The next step in treatment after trying opioid and 
pharmacologic therapy is interventional therapy. There are many options for this approach in 
treatment, which also have great results. Some examples of these interventional therapies include 
nerve blocks, a kyphoplasty, a vertebroplasty, and joint injections (Copenhaver, 2019). Case 
studies show that the options for interventional therapies are very effective resulting in pain 
relief. For example, there is a 2017 explaining how 6 patients received joint injections because of 
tumors causing pain. The pain relief from these injections lasted about eight months with a 
decrease in the use of opioids as well (Gulati, 2016). Because of the positive results from the 
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interventional therapies, perhaps this line of treatment should be suggested as first-line along 
with opioid treatment, giving patients more options and advocacy for their plan of care.  
 
Review of Literature 
Cancer produces many symptoms, and pain is one of them. When a person is having pain 
due to cancer, many aspects of the person’s life may be altered or inhibited; for example, 
activities of daily living may be difficult to perform, their psychological state may be altered, 
their social lives may be changed, and their overall physical function may be affected in a way 
that the person may need to modify what they typically do in a normal day. The pain a person 
experiences depends on the type of cancer, how far the cancer has progressed, and the treatment 
being performed. Statistics show that 33-59% of people who are undergoing cancer treatment 
experience chronic pain and increases to 64-74% in people with more advanced diseases 
(Dhingra, 2019). Because cancer results in a high prevalence of reported pain, patients should be 
routinely screened for pain through a cancer pain assessment.  
Because cancer pain is such a complex symptom of cancer, the cancer pain assessment 
should be an in-depth evaluation resulting in a specialized plan of care. The first step of this 
evaluation starts with a comprehensive assessment of their pain history, the cancer they currently 
have that is causing the pain, and the treatment they are receiving. One important aspect to assess 
is their psychosocial status along with their physical functioning status because, as previously 
stated, pain may alter these aspects of a person’s life. A comprehensive physical exam and 
assessment of the pain location should be completed in addition to receiving a description of the 
pain from the patient. “The description of the pain must include the intensity, temporal features, 
location and patterns of radiation, quality, and factors that provoke or relieve the pain” (Dhingra, 
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2019). All of these things including the data received from imaging and other tests in 
combination help the professional medical team to determine the etiology and pathophysiology 
of the pain being experienced. In addition to the objective data, a numerical pain scale is used to 
determine the severity of the pain. The pain scale starts at 0 and goes to 10, 0 referring to no pain 
and 10 referring to the worst pain (Aono, 2020). After this is all retrieved, a diagnosis may be 
determined, and a plan of care is then formed in order to relieve the pain.  
The goal of treatment is to maximize the functioning of the person while decreasing the 
possibility or presence of adverse effects occurring with the treatment being given. Routine 
cancer pain assessments are important because it allows the clinicians and practitioners to see the 
response to the treatment and find new targets for pain treatment. The pain being experienced 
may be reversible; however, persistent and chronic pain will most likely not be completely 
eradicated. “Persistent pain is defined as pain that continues beyond the expected time of healing, 
or for at least three to six months” (Galicia-Castillo, 2019). The goals must be realistic, which is 
why optimal functioning is a great goal to strive towards. Statistics show that there is a sufficient 
amount of pain relief in 70-90% of patients who abide by the treatment plan of care (Ahmed, 
2019). Even with these statistics, there are cancer pain patients who are being undertreated or 
their goals are not being reached. In 2014, there was a systematic review performed that resulted 
in a decrease in 25% of undertreated patients between the years 2008 and 2013; however, there 
are still one-third of patients with cancer pain who are still being undertreated. There are many 
adverse effects on a person’s life when they are being undertreated, such as a poor ability to cope 
with the illness, dysfunction with activities of daily living, hardships with physical and social 
life, readmissions into the hospital, and interreference with chemotherapy and radiation 
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treatments. This is another reason why it is important for cancer pain reassessments, which 
would aid in the redirection of treatment to a more effective plan of care.  
The World Health Organization (WHO) analgesic ladder approach was published in the 
mid- 1980s, which gave clinicians and practitioners a stepwise or stepped care approach to 
strategize a therapeutic response from treatment depending on the description of the pain, 
ranking it from mild to severe. The ladder highlights opioids being prescribed for moderate to 
severe pain, along with suggesting combination therapy throughout and adjuvant analgesics. 
“Adjuvant analgesics (or coanalgesics) stands for any drug with a major clinical use other than 
pain that is used as an analgesic in selected circumstances” (Ahmed, 2019). The patient that 
describes their pain as moderate should be prescribed Acetaminophen or an NSAID initially. 
These analgesics may be combined with adjuvant drugs for additional analgesia, such as an 
analgesic antidepressant. The adjuvant drug may also be used to treat other adverse effects or 
other symptoms from the cancer pain. The ladder also emphasizes that patients with moderate to 
severe cancer pain or chronic pain should be treated with an opioid or if the NSAIDs are not 
reaching a therapeutic range. As previously stated, these drugs may also be paired with adjuvant 
analgesics. With the stepped care approach in older adults, the overall idea is that systemic 
medications are used later in treatment, or as the pain worsens, because of the potential for 
toxicity, adverse effects, and interactions with other prescribed medication. Interventional 
therapies should also be explored firsthand, and surgical intervention should be explored once a 
disease has progressed to a persistent pain state. There are also times when chemotherapy is 
given palliatively to treat pain as pancreatic cancer patients have a lot of pain. Chemo has the 
potential to shrink the tumor enough to hopefully alleviate some of the pain.  
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The use for opioid therapy is considered the first-line approach for cancer pain patients 
with moderate to severe pain, as shown by the WHO analgesic ladder. Opioids are a common 
therapy for cancer pain patients because of the safety with this therapy related to dose titration, 
the variety of routes used for administration, reliability, and effectiveness for many different 
types of pain (Ahmed, 2019). Opioids bind to many different kinds of receptors throughout the 
body, including in the peripheral and central nervous system. The most analgesic-producing 
receptors are the Mu receptors, which are what most opioids are targeted to bind to for highest 
rate of effectiveness. Chronic cancer pain is typically treated with a long-term treatment of pure 
Mu receptor agonists (Ahmed, 2019). Some examples of Mu receptor agonists are morphine, 
hydromorphone, oxycodone, oxymorphone, fentanyl, and methadone. Statistics show that 
chronic cancer pain is reported by about 30-50% of patients along with 75-90% of patients with 
other advanced diseases – these reports justify an opioid treatment plan (Ahmed, 2019).   
The United States has assigned opioids as controlled substances under the Controlled 
Substances Act. This federal law places controlled substances under a list ranking the drugs from 
schedules of one to five based on the ability of the drugs to be abused – most opioids for cancer 
pain are schedule II, which would indicate a higher ability to abuse the drug. The government 
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has also taken steps to further prevent abuse and overdose from happening through two more 
opioid-regulating strategies. Through the Risk Evaluation and Mitigation Strategy (REMS), there 
are regulations on extended-release and long-acting opioids in addition to another regulation on 
transmucosal immediate-release fentanyl (TIRF) formulations (Ahmed, 2019). Because of this, 
the undergoing of opioid therapy must be performed with caution while having the patient on 
this therapy closely monitored with routine reassessments. Even so, there are clinicians and 
practitioners who are concerned about prescribing opioids because of these laws, which could 
potentially lead to the already spoken about undertreatment of pain. There are some questions 
that should be asked when starting a patient on an opioid regimen: “Is there an alternative 
therapy that is likely to have an equivalent or better therapeutic index for pain control, functional 
restoration, and improvement in quality of life?; Does the patient have medical problems that 
may increase the risk of opioid-related adverse effects?; Is the patient likely to manage the opioid 
therapy responsibility or relevant caregiver likely to responsibly co-manage? (Galicia-Castillo, 
2019).” These are things to consider for the patient before starting an opioid treatment plan 
because of the numerous amounts of side effects and the potential to abuse the drugs.  
There are many potential side effects or adverse effects from a plan of care involving 
opioid therapy for cancer pain. The use of opioids in general increases the risk of abuse or 
addiction without the proper monitoring and prescribing. Opioids work by activating the 
dopamine reward pathways in the brain that can release a euphoria effect, which makes the drugs 
easier to result in addiction and abuse (Ahmed, 2019). This abuse is not completely uncommon 
in patients with cancer pain, as a study of 432 patients with cancer pain using opioids for 
palliative care showed that 18% of these patients were using the opioids out of their prescribed 
plan of care to cope with the illness (Ahmed, 2019). The incorrect use of opioids for cancer pain 
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may interfere with the effectiveness of the treatment they are receiving. Even so, overdoses and 
hospitalizations for cancer pain related opioid use are uncommon. With the patients being closely 
monitored and reassessed, a risk assessment should also be performed to ensure the patient’s 
safety: observe for a personal history of alcohol or drug abuse, family history of alcohol or drug 
abuse, and a major psychiatric disorder. Encouragement of the patient to adhere to the plan of 
care is crucial for their safety along with limiting the quantity of drugs used and no early refills. 
Pain contracts should be used in combination with drug screening to ensure the medications are 
being taken.  
The most common side effects from opioids include gastrointestinal (GI) and 
neurological issues. Opioids are typically known for their GI effects, such as constipation. The 
cause of this is most commonly decreased activity of the GI tract, or decreased peristalsis. There 
are other results from this as well, such as nausea, pain, and bloating. In cancer patient using 
opioid therapy, rates of constipation are around 60-90% (Ahmed, 2020). Narcotic bowel 
syndrome is a term that can be used when the pain is significant in the abdomen with increasing 
the use of opioids. This is a paradoxical effect because the pain is worsening with opioid use 
even though opioids are a type of analgesic medication.  
The other most common side effect is the neurological issues involving somnolence 
and/or mental clouding. These issues are typically at their worst when initiating opioid therapy or 
increasing the dose of the drug being used. The clinical manifestations vary depending on the 
person but can be shown in various degrees of inattention or fatigue, disorientation, severe 
memory impairment, or extreme confusion and delirium (Ahmed, 2020). There was a cross-
sectional study performed involving 1915 patients with cancer who were beginning their opioid 
therapy treatment plan and had been taking opioids for at least three days. The study recorded the 
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degree of cognitive impairment based on the Mini-Mental Status Examination (MMSE). The 
results indicated that one-third of the population had scores less than 27, indicating slight 
cognitive dysfunction (Ahmed, 2020).  
As previously stated, there are many side effects resulting from the use of opioids for 
cancer pain management; however, there are side effects that are not as common as others. 
Nausea and vomiting may occur at the initiation of the opioid therapy but does not persist 
because of the tolerance effect opioids can. A sign of neurotoxicity is myoclonus, which is the 
uncontrollable spasming of muscles. This is a sign that the dose is too high and is often 
accompanied by somnolence and mental clouding. In addition, there may be a decrease in sex 
hormones because opioids affect the hypothalamic-pituitary-adrenal axis. Some respiratory 
issues involve an opioid-induced sleep-disordered breathing, which would be caused by someone 
already having sleep apnea, and respiratory depression, which rarely happens even though it is 
commonly considered to be a serious adverse effect. In a systematic review and meta-analysis, 
there were reports of 91% of patients having sleep disordered breathing receiving opioids in 
sleep clinics and 63% of patients in pain clinics (Arif, 2020). Because of these statistics, these 
patients should be closely monitored. Pruritus is seen in about 2-10% of patients receiving opioid 
therapy along with the rare account of an allergic reaction. Urinary retention is a possibility 
because the opioids attach to a receptor that may result in total bladder relaxation. Infection risk 
has been shown by four different epidemiologic studies to be a side effect of opioids because 
some of them have immunosuppressive qualities. Finally, opioid induced hyperalgesia can occur, 
which is also a paradoxical response that is shown by a patient receiving opioids becoming more 
sensitive to some types of painful stimuli, or in extreme cases, experience pain from stimuli that 
typically would not be painful, or allodynia (Ahmed, 2020).  
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There are many things to consider when prescribing opioids to a patient with cancer pain. 
Each person is different, so every person will respond differently to the opioid treatment plan. 
This also includes each person’s reaction to the adverse effects that go along with this kind of 
treatment, which may be because of many personal characteristics, such as age, genetics, other 
drugs they might be on, and comorbidities (Ahmed, 2020). There should also be consideration 
based on their social and psychological factors, such as depression, anxiety, coping skills, 
support, and financial status. Two comorbidities that are of great importance include renal 
insufficiency and liver failure. Because some opioids result in active metabolites accumulating 
then being excreted by the renal system, this would be unsafe for a patient with renal 
insufficiency because of side effects and potentially toxicity. Because most opioids are 
metabolized by the liver, patients with liver failure would be at risk for side effects (Ahmed, 
2020). Other comorbidities to look out for include obesity, sleep disturbances, such as sleep 
apnea, dementia or any type of cognitive impairments, history of falls and uneasy gait, 
hypertension, congestive heart failure, and constipation.  
As there are many risks to starting an opioid regimen for cancer pain, there are also many 
benefits. One benefit to the opioid plan of care is that there are numerous routes of 
administration, the favored routes being oral, transdermal, subcutaneous, intravenous, 
intrathecal, and intraspinal. The oral route is deemed the easiest by patients because there is 
flexibility to it and is extremely convenient (Ahmed, 2020). The transdermal route is often used 
for the use of chronic pain and may be favored over the oral route due to the GI effects caused by 
digestion of the medication, such as constipation; however, the patient must contain enough 
adipose tissue for the transdermal route to result in therapeutic treatment. The subcutaneous and 
intravenous routes are typically only temporary, and these regimens begin when other routes 
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need to be switched for a period of time. Finally, the intrathecal and intraspinal routes have been 
shown to be extremely effective in the controlling of the cancer pain and produce fewer side 
effects (Ahmed, 2019). 
As previously stated, each person with an opioid regimen will respond to each drug in a 
different and nonpredictable way. This is very much involved in dose titration, which is another 
benefit of an opioid regimen. Each regimen is individualized, based on needs and desired 
outcomes for each patient. The goal of dose titration is to have a therapeutic analgesic response 
with the fewest side effects possible; however, that is not always the case. The dose will be 
increased until the person experiences the analgesia with side effects or until the side effects 
become unbearable for the patient. During the dose titration process, each patient is monitored 
extremely closely for side effects and especially toxicity. If a dose becomes extremely high, there 
will be a reassessment to make sure that specific drug is still beneficial for the patient and their 
treatment plan (Ahmed, 2019). Even so, cancer patients typically do not have extremely high 
doses.   
There is a point in dose titration where a patient may be deemed poorly responsive to the 
opioid regimen because of side effects or the benefits no longer outweigh the adverse effects, 
which could lead to multiple options being explored to reach analgesia. There could be a trial of 
another opioid being used, direct management of the side effects, or adding other therapies to the 
equation, such as nonopioids, adjuvant analgesics, or nonpharmacologic therapy. The action of 
trying a different opioid rather than the one being used previously is called opioid rotation 
(Ahmed, 2019). This is a great option for when a patient responds poorly to another opioid. The 
idea and goal of this action is to provide a balance between analgesia and side effects, which 
would be another benefit to an opioid regimen – it is flexible. Another aspect to this idea of 
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being poorly responsive to a regimen, is that a person could potentially become tolerant to the 
adverse effects of the drugs over a few weeks of treatment (Ahmed, 2019). Even so, if the patient 
were to switch to another drug during a time of opioid rotation, the new opioid could have even 
stronger effects, which might not be worth the waiting time for tolerance to begin.  
There is an analysis of Cochrane reviews (152 studies, including 13,524 patients) that 
resulted in 19 out of every 20 people with the description of pain being moderate to severe 
cancer pain on an opioid regimen should have had their pain reduced to mild or moderate or no 
pain within fourteen days. Most of the patients experienced adverse effects, and one to two of 
every ten patients being treated would find these adverse effects intolerable, leading to a change 
in treatment (Ahmed, 2019). Even so, the studies included small group settings for review and 
few follow-up meetings with the patients, so the level evidence is not very high.  
Patients who do not tolerate first-line treatments, such as opioids, should explore 
interventional therapies. Interventional refers to therapies that are invasive with the goal of 
analgesia with many options, such as injection therapies, spine-related injections, 
vertebroplasties and kyphoplasties, neural blockades, neuraxial infusions, intrathecal catheter 
placement, and intraventricular opioid delivery. These approaches are oriented towards giving 
safe and effective pain relief. The idea of interventional therapy is used when the benefits no 
longer outweigh the risks for pharmacotherapy. Although the effects tend to be positive, because 
they are invasive, they automatically increase the risk for infection.  
Cancer pain patients have effective options to attempt with the goal of effective pain 
relief. Soft tissue and joint injections are a great option for cancer pain patients as long as there 
are no contraindications for injections, such as coagulopathy, leukopenia, pneumothorax, or 
infection. One of the benefits to this type of interventional therapy is that the pain from the 
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injection is relieved for days or even weeks.  Another type of interventional therapy is the spine-
related injection, which are typically for acute and chronic, non-cancer, low back and neck pain 
but can also be useful for patients with cancer pain involving other approaches including epidural 
steroid injections, facet joint injections, facet denervation approaches, and sacroiliac injections. 
One 2017 case study consisting of 6 patients each receiving joint injections because of sacroiliac 
tumors causing pain. Pain scales were recorded before and after the procedures, resulting in a 
significant pain improvement that lasted for about eight months for each person. In addition, 
each person decreased their use of opioids because of their pain relief from the procedure 
(Gulati, 2016). 
Other options for interventional therapies include a vertebroplasty and kyphoplasty. 
Vertebroplasties involved the injection of a medical cement into a vertebral body known as a 
compression fracture in order to stabilize the spine. Kyphoplasties involves something called a 
“inflatable bone tamps,” which is basically a balloon that is inflated and releases the pressure 
from the collapsed vertebral body creating an area where cement may be injected like the 
vertebroplasty (Copenhaver, 2019). There is a 2016 case study performed on 158 patients with 
228 cancer-related vertebral compression fractures who had chosen to do the kyphoplasty. The 
results were recorded right after the procedure and three months after. The result of the study 
concluded a decreased mean pain score from 7.5 to 3.6 with a decreased disability index from 50 
to 42. Cement leaks are a rare complication; however, in this study, there was a result of 31% 
(Hargunani, 2016). The results showed that pain was relieved and controlled in over one-half of 
the patients, which also resulted in a decrease in medications for pain management and pain 
disability scores. In addition, the kyphoplasty procedures resulted in the decreased need for 
medications of any kind, walking aids, such as canes and braces, and a decreased prevalence for 
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bedrest (Copenhaver, 2019). The benefits from these procedures are strong; however, there are 
still some complications and things to take account for, such as a pulmonary embolism, spinal 
cord compression, and paraplegia. Even so, the risk of these adverse effects happening is 
relatively low.  
The next interventional therapy that will be discussed are neural blockades. The 
procedure of nerve block injections includes injecting a drug within close proximity of a nerve in 
hopes for a result of pain relief. Therapeutic nerve blocks are providing pain relief for a longer 
period of time. Nerve blocks can be divided into a neurolytic procedure or a nonneurolytic 
procedure (Copenhaver, 2019). A neurolytic procedure involves the alteration of a nerve, 
potentially permanently injuring it. A nonneurolytic procedure involves preserving the nerve 
with no injury. The experience with these types of procedures for cancer pain has shown to be 
beneficial through the recording of case reports and other clinicians and practitioners. Yes, these 
procedures are beneficial; however, nerve blocks should not be considered until all other options 
have been explored. This is because of the risk of neuritis, which is a type of nerve pain, the 
possibility of some type of neurological compromise, tissue damage resulting from the neurolytic 
procedures, and insufficient reach of therapeutic levels of analgesia (Copenhaver, 2019). There is 
a block, though, that is safe and effective and used routinely for cancer pain patients when their 
first-line therapy with medication does not suffice. This blockade is called the Celiac Plexus 
Neurolysis (CPN), which is commonly used for pain occurring because of some type of 
abdominal cancer, typically pancreatic cancer (Copenhaver, 2019). For neurolytic blockades in 
general, there are many risks that are involved with the procedures. For example, there could be 
a result of some type of autonomic dysfunction, bladder and/or bowel dysfunction, orthostatic 
hypotension, neuritis, and anesthesia. 
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One interventional therapy that includes targeted drug delivery is neuraxial infusion. This 
type of drug therapy involves using a neuraxial space, such as an epidural space and intrathecal 
space. There are multiple options for the infusion of this drug therapy, such as different infusion 
devices along with different drugs available. This treatment is optimal for cancer pain patients 
because the pain is targeted and has a high potential for the relief of this pain. Even so, the risks 
and benefits need to be weighed. One type of neuraxial infusion that has been very successful is 
the intrathecal drug delivery. This therapy involves the same targeted therapy as stated before 
and is typically used for cancer pain patients. The final type of neuraxial infusion discussed is the 
intraventricular opioid therapy, which involves a drug being injected into the cerebral ventricles 
in the brain through an infusion device. The evidence proving this therapy is greater than opioid 
therapy is extremely weak; however, the experience from the procedure has shown 50-90% of 
cancer pain patients have strong pain relief (Copenhaver, 2019).  
There was a case study performed recording the beneficial aspects of using intrathecal 
drug delivery. The case study involved a randomized trial consisting of 202 patients with cancer 
pain that was not being managed and treated in the most efficient way. The pain was not 
controlled. The requirement for the patients to receive the intrathecal drug delivery was that they 
had to tolerate intrathecal morphine administration over a four-week assessment. The other 
option for the patients was a conventional medical management therapy, which involved any 
therapy other than spinally administered medication. Both groups increased cancer pain relief, 
however, there was a greater than 20% difference in the intrathecal group with the most pain 
relief. They also reported a decrease in toxicity from 58% to 38%. There were also decreased 
amounts of side effects resulting from the intrathecal therapy along with a longer survival period 
Review of Literature 
 
15 
being about six months longer. There was a six month follow up after the study was performed, 
and the results remained the same (Copenhaver, 2019). 
 
Conclusion 
 Overall, opioid therapy treatment has been effective, even though there are many possible 
adverse effects. Because the adverse effects can be so prominent, patients tend to try other 
options to treat their pain, such as interventional therapies, nonpharmacologic therapies, and 
combination therapies. There are many options to attempt resolving pain in cancer patients, 
which is necessary because cancer pain is complex. The option of interventional therapies should 
be approached alongside opioid therapy in the first-line of treatment because they are extremely 
effective. There are more invasive procedures; however, case studies and reports have shown 
that the interventional therapies could be equally if not more effective than opioids, depending 
on the person and their preferences. Multiple options for treatment should be addressed, and 
patients should play a role in managing their pain. Educating patients about the risks and benefits 
of treatment modalities should be done so that the provider and patient can make an 
individualized treatment plan.   
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